SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/078001
(MODIFIED)		Serial No.	10/530,950
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Applicant	FRYNS et al.
		Filing Date	April 8, 2005
		Group	To Be Assigned
		IDS Filed	July 21, 2005

			U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
/J.G./	6,228,582 B1	05/08/2001	Rodier et al.			
	FOR	EIGN PATENT	 OR PUBLISHED FOREIGN PATENT	APPLICATION	ON	
Examiner's Initials	Document Publication Country or Class Subclass Number Date Patent Office					Translation (Yes/No)
	OTHER DOC	UMENTS (INCL	UDING AUTHOR, TITLE, DATE, PL	ACE OF PUB	LICATION)	
/J.G./			nguage Phenotypes Strengthens Ev 5:539-547 (2001).	idence of Link	rage to Autisr	m", American
/J.G./	Smith et al., "Mo and Auditory Pro	lecular Genetic occessing Deficits	Delineation of a Deletion of Chromos *, Cytogenet Genome Research, 98:	iome 13q12 - 233-239 (200	→q13 in a Pat 2).	tient with Autism
/J.G./	Steele et al., "Brief Report: A Case of Autism with Interstitial Deletion of Chromosome 13", Journal of Autism and Developmental Disorders, 31:231-234 (2001).					
/J.G./			rotein Kinase A-Anchoring, beige/Ch The Journal of Neuroscience, 20:855			nolog Implicated
/J.G./	PCT/BE03/0017	PCT/BE03/00172 International Search Report mailed March 23, 2004				
/J.G./	PCT/BE03/00172 International Preliminary Examination Report mailed January 21, 2005					

EXAMINER	/Jaime Greene/	DATE CONSIDERED	10/12/2007
	tial citation considered. Draw line through citation	n if not in conformance and	not considered. Include copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/078001
(MODIFIED)		Serial No.	10/530,950
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Applicant Fryns et al.	
		Filing Date	April 8, 2005
		Group	1634
		IDS Filed	August 3, 2007

		U.S. PAT	ENT DOCUMENTS	
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	
/J.G./	4,518,584	May 21, 1985	Mark et al.	
/J.G./	4,683,195	Jul. 28, 1987	Mullis et al.	
/J.G./	4,683,202	Jul. 28, 1987	Mullis et al.	
/J.G./	4,737,462	Apr. 12, 1988	Mark et al.	
/J.G./	4,800,159	Jan. 24, 1989	Mullis et al.	
/J.G./	4,965,188	Oct. 23, 1990	Mullis et al.	
/J.G./	5,405,943	Apr. 11, 1995	Comings	
/J.G./	5,686,311	Nov. 11, 1997	Shaw	

	FOREIG	ON PATENT OR PUBL	ISHED FOREIGN PATENT APPLICATION	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
/J.G./	WO 02/068663	Sep. 6, 2002	WIPO	

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/J.G./	GenBank Accession No. AF467288	
/J.G./	GenBank Accession No. NM015678	
/J.G./	GenBank Accession No. NT009984	
/J.G./	GenBank Accession No. Y18276	Y.,
/J.G./	Gilbert et al., "The neurobeachin gene (Nbea) identifies a new region of homology between mouse central Chromosome 3 and human Chromosome 13q13," <i>Mamm. Genome</i> 10(10):1030-1 (1999).	

EXAMINER	/Jaime Greene/	DATE CONSIDERED	10/12/2007	
	ial citation considered. Draw line through citatio	n if not in conformance and	d not considered. In	clude copy of this

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/078001
(MODIFIED)		Serial No.	10/530,950
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Fryns et al.	
		Filing Date	April 8, 2005
		Group	1634
(37 C.F.R. § 1.98(b))		IDS Filed	August 3, 2007

	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)
/J.G./	Keenan et al., "Isoform specificity of activators and inhibitors of protein kinase C γ and δ," FEBS Letters 415:101-8 (1997).
/J.G./	Smith et al., "Yeast PKA represses Msn2p/Msn4p-dependent gene expression to regulate growth, stress response and glycogen accumulation," <i>EMBO J.</i> 17:3556-64 (1998).
/J.G./	Sui et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>Proc. Natl. Acad. Sci. USA</i> 99(8):5515-20 (2002).